Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma

Ali Shamseddine, Youssef H Zeidan, Ziad El Husseini, Malek Kreidieh, Monita Al Darazi, Rim Turfa, Joseph Kattan, Ibrahim Khalifeh, Deborah Mukherji, Sally Temraz, Kholoud Alqasem, Rula Amarin, Tala Al Awabdeh, Samer Deeba, Faek Jamali, Issa Mohamad, Mousa Elkhaldi, Faiez Daoud, Mahmoud Al Masri, Ali Dabous, Ahmad Hushki, Omar Jaber, Maya Charafeddine, Fady Geara, Ali Shamseddine, Youssef H Zeidan, Ziad El Husseini, Malek Kreidieh, Monita Al Darazi, Rim Turfa, Joseph Kattan, Ibrahim Khalifeh, Deborah Mukherji, Sally Temraz, Kholoud Alqasem, Rula Amarin, Tala Al Awabdeh, Samer Deeba, Faek Jamali, Issa Mohamad, Mousa Elkhaldi, Faiez Daoud, Mahmoud Al Masri, Ali Dabous, Ahmad Hushki, Omar Jaber, Maya Charafeddine, Fady Geara

Abstract

Background: Neoadjuvant chemotherapy and short-course radiotherapy followed by resection has been gaining recognition in the treatment of rectal cancer. Avelumab is a fully human immunoglobulin that binds Programmed Death-Ligand 1 (PD-L1) and prevents the suppression of the cytotoxic T cell immune response. This phase II trial evaluates the safety and pathologic response rate of short-course radiation followed by 6 cycles of mFOLFOX6 with avelumab in patients with locally advanced rectal cancer (LARC).

Methods: This study is prospective single-arm, multicenter phase II trial adopting Simon's two-stage. Short-course radiation is given over 5 fractions to a total dose of 25 Gy. mFOLFOX6 plus avelumab (10 mg/kg) are given every 2 weeks for 6 cycles. Total mesorectal excision is performed 3-4 weeks after the last cycle of avelumab. Follow up after surgery is done every 3 months to a total of 36 months. Adverse event data collection is recorded at every visit.

Results: 13 out of 44 patients with LARC were enrolled in the first stage of the study (30% from total sample size). All patients met the inclusion criteria and received the full short-course radiation course followed by 6 cycles of mFOLFOX6 plus avelumab. 12 out of the 13 patients completed TME while one patient had progression of disease and was dropped out of the study. The sample consisted of 9 (69%) males and 4 (31%) females with median age of 62 (33-73) years. The first interim analysis revealed that 3 (25%) patients achieved pathologic complete response (pCR) (tumor regression grade, TRG 0) out of 12. While 3 (25%) patients had near pCR with TRG 1. In total, 6 out of 12 patients (50%) had a major pathologic response. All patients were found to be MMR proficient. The protocol regimen was well tolerated with no serious adverse events of grade 4 reported.

Conclusion: In patients with LARC, neoadjuvant radiation followed by mFOLFOX6 with avelumab is safe with a promising pathologic response rate. Trial Registration Number and Date of Registration ClinicalTrials.gov NCT03503630, April 20, 2018. https://ichgcp.net/clinical-trials-registry/NCT03503630?term=NCT03503630&draw=2&rank=1 .

Keywords: Chemotherapy; Immunotherapy; Neo-adjuvant therapy; Radiotherapy; Rectal cancer.

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Fig. 1
Fig. 1
Treatment protocol
Fig. 2
Fig. 2
Consort diagram

References

    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551.
    1. Fernandez-Martos C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol. 2015;26(8):1722–1728. doi: 10.1093/annonc/mdv223.
    1. Willett CG. Management of locoregional rectal cancer. J Natl Compr Cancer Netw. 2018;16(5S):617–619. doi: 10.6004/jnccn.2018.0037.
    1. Marco MR, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum. 2018;61(10):1146–1155. doi: 10.1097/DCR.0000000000001207.
    1. Quah HM, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113(1):57–64. doi: 10.1002/cncr.23516.
    1. de Rosa N, et al. DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics. J Clin Oncol. 2016;34(25):3039–3046. doi: 10.1200/JCO.2016.66.6826.
    1. Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi: 10.1056/NEJMoa1500596.
    1. Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–5388. doi: 10.1158/1078-0432.CCR-09-0265.
    1. Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019;95(7):936–939. doi: 10.1080/09553002.2019.1623429.
    1. Demaria S, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728–734.
    1. Taube JM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31(2):214–234. doi: 10.1038/modpathol.2017.156.
    1. Dovedi SJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468. doi: 10.1158/0008-5472.CAN-14-1258.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Bethesda: Biometric Research Branch, National Cancer Institute; 1989. pp. 1–10.
    1. Cercek A, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071. doi: 10.1001/jamaoncol.2018.0071.
    1. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–1933. doi: 10.1200/JCO.2011.40.1836.
    1. Baeten CI, et al. Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(4):1219–1227. doi: 10.1016/j.ijrobp.2006.07.1362.
    1. Nilsson PJ, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial. BMC Cancer. 2013;13:279. doi: 10.1186/1471-2407-13-279.
    1. Tintelnot J, Stein A. Immunotherapy in colorectal cancer: available clinical evidence, challenges and novel approaches. World J Gastroenterol. 2019;25(29):3920–3928. doi: 10.3748/wjg.v25.i29.3920.
    1. Goodman KA. Definitive chemoradiotherapy ("Watch-and-Wait" Approach) Semin Radiat Oncol. 2016;26(3):205–210. doi: 10.1016/j.semradonc.2016.02.003.
    1. Maas M, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–4640. doi: 10.1200/JCO.2011.37.7176.
    1. Smith JJ, et al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767. doi: 10.1186/s12885-015-1632-z.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi